TY - JOUR
T1 - Excellent survival regardless of disease stage in patients with advanced nasopharyngeal cancer
AU - Belgioia, Liliana
AU - Bacigalupo, Almalina
AU - Vecchio, Stefania
AU - Marcenaro, Michela
AU - Pupillo, Francesco
AU - Agostinelli, Stefano
AU - Corvò, Renzo
PY - 2016/7/1
Y1 - 2016/7/1
N2 - Background: We present our experience in assessing the feasibility and efficacy outcomes of intensified intensitymodulated radiation therapy (IMRT) with simultaneous integrated boost (SIB) delivered to patients with nasopharyngeal carcinoma (NPC). Methods: Between March 2009 and December 2014, 35 patients affected by advanced NPC with a median age of 53 years (range 11-77) were treated with definitive radiotherapy. Radiotherapy was delivered by helical tomotherapy with the SIB technique. The prescribed doses were 66 Gy to macroscopic disease, 60 Gy to high-risk subclinical disease, and 54 Gy to low-risk disease in 30 fractions. The daily SIB dose was 2.2 Gy to macroscopic disease. Results: At the end of treatment 33 (94%) patients had obtained complete clearance of disease and 2 patients had died (1 of persistent disease after 3 months and 1 of cancer-unrelated causes after 4 months). At a median follow-up of 40 months (range 5-69), locoregional control rates at 2 and 4 years were 92.9% and 88.2%, respectively, and the overall survival after 4 years was 93.9%. The most significant acute toxicities were grade 2 and 3 mucositis (43%). No grade 3 and 4 late toxicities were observed; grade 2 xerostomia after 6 months from the end of treatment was reported in 11 patients; xerostomia toxicity decreased to grade 1 in 6/11 patients within 12 months. Conclusions: These results show that intensified IMRT with SIB is an excellent strategy offering high local control rates for NPC patients with mild acute and late toxicity.
AB - Background: We present our experience in assessing the feasibility and efficacy outcomes of intensified intensitymodulated radiation therapy (IMRT) with simultaneous integrated boost (SIB) delivered to patients with nasopharyngeal carcinoma (NPC). Methods: Between March 2009 and December 2014, 35 patients affected by advanced NPC with a median age of 53 years (range 11-77) were treated with definitive radiotherapy. Radiotherapy was delivered by helical tomotherapy with the SIB technique. The prescribed doses were 66 Gy to macroscopic disease, 60 Gy to high-risk subclinical disease, and 54 Gy to low-risk disease in 30 fractions. The daily SIB dose was 2.2 Gy to macroscopic disease. Results: At the end of treatment 33 (94%) patients had obtained complete clearance of disease and 2 patients had died (1 of persistent disease after 3 months and 1 of cancer-unrelated causes after 4 months). At a median follow-up of 40 months (range 5-69), locoregional control rates at 2 and 4 years were 92.9% and 88.2%, respectively, and the overall survival after 4 years was 93.9%. The most significant acute toxicities were grade 2 and 3 mucositis (43%). No grade 3 and 4 late toxicities were observed; grade 2 xerostomia after 6 months from the end of treatment was reported in 11 patients; xerostomia toxicity decreased to grade 1 in 6/11 patients within 12 months. Conclusions: These results show that intensified IMRT with SIB is an excellent strategy offering high local control rates for NPC patients with mild acute and late toxicity.
KW - Helical tomotherapy
KW - Intensity modulated radiotherapy
KW - Nasopharyngeal cancer
KW - Simultaneous integrated boost
UR - http://www.scopus.com/inward/record.url?scp=84984704746&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84984704746&partnerID=8YFLogxK
U2 - 10.5301/tj.5000483
DO - 10.5301/tj.5000483
M3 - Article
AN - SCOPUS:84984704746
VL - 102
SP - 381
EP - 386
JO - Tumori
JF - Tumori
SN - 0300-8916
IS - 4
ER -